Key result
Omentin-1 retarded aortic atherosclerotic lesions in Apoe(-/-) mice and its levels were reduced in coronary endothelium but increased in plasma and atheromatous plaques in CAD patients.
Why the study?
Does omentin-1 prevent atherogenesis in preclinical models and correlate with CAD in humans?
Population
Human monocyte-derived macrophages, human aortic smooth muscle cells in vitro, Apoe mice in vivo, and human…
Comparison
Omentin-1 vs Control/vehicle and non-CAD patients
Design
Preclinical
Follow-up
4 weeks (in vivo mouse model)
Authors
Loading...
Hypothesis-generating for omentin-1 in atherosclerosis; prospective human trials needed before clinical consideration.
Does omentin-1 prevent atherogenesis in preclinical models and correlate with CAD in humans?
Omentin-1 demonstrates significant atheroprotective effects in vitro and in vivo, suggesting it may serve as a novel therapeutic target for atherosclerosis and CAD.
Watanabe et al. (2016) studied Coronary artery disease and atherosclerosis. Omentin-1 vs. non-CAD patients (human) / control (mice) was evaluated on Atherosclerotic lesion development and omentin-1 expression levels. Omentin-1 retarded aortic atherosclerotic lesions in Apoe(-/-) mice and its levels were reduced in coronary endothelium but increased in plasma and atheromatous plaques in CAD patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: